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Abstract
Background:  The current study correlates cytologic morphology with histologic type and
describes immunophenotypes with a focus on epithelial, neuroendocrine, and lymphoid
characteristics in an institutional series of surgically excised thymomas.
Methods: Fine needle aspirates (FNAs) and surgical specimens were retrospectively analyzed, and
immunohistochemical stains were performed for EMA, cytokeratin 7, cytokeratin 20, CD57 CD5,
bcl-2, calretinin, vimentin, CD3, CD20, CD1a, CD99 and Ki67. Tumors were classified by WHO
criteria.
Results: There were eleven male and six female patients with an age range of 41 to 84 years (mean,
61 years) and a male to female ratio of 1.8:1. Four thymomas (4/17, 23.5%) were associated with
neuromuscular disease: myasthenia gravis (n = 3) and limbic encephalitis (n = 1). FNA, under CT
guidance, was performed in 7 cases. The positive predictive value for thymoma by FNA cytology
was 100% and the sensitivity was 71%. Thymomas associated with neuromuscular disorders were
WHO types B2 (n = 1) and B3 (n = 3), and showed a strong expression of CD57 in the majority
of neoplastic epithelial cells accompanied by large numbers of CD20+ intratumoral B lymphocytes.
Two of seventeen (11.7%) thymoma s  ( a l l  s p o r a d i c  B 3  t y p e )  c o n t a i n e d  n u m e r o u s  n e o p l a s t i c
epithelial cells positive for CD5 and bcl-2.
Conclusion: Our results suggest that thymomas associated with autoimmune disorders contain a
significant population of CD20+ intratumoral B lymphocytes. Strong CD57 positivity in thymomas
may suggest a concomitant neuromuscular disorder, notably myasthenia gravis. CD5 expression is
of limited value in the differential diagnosis of primary thymic epithelial neoplasms since both thymic
carcinomas and thymomas may express CD5.
Background
Thymoma is a primary mediastinal neoplasm arising from
or exhibiting differentiation towards thymic epithelial
cells, typically with the presence of non-neoplastic lym-
phocytes [1]. The overall incidence of thymoma in the US
is 0.15 per 100,000 person-years [2]. The cause of thy-
moma is unknown [3]. The histological classification of
thymoma has remained controversial since 1999, when
the World Health Organization (WHO) Consensus Com-
mittee published a histologic typing system for tumors of
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the thymus [4]. The 2004 WHO Classification of Lung,
Pleura, Thymus and Heart Tumors [1] maintained the
skeleton of the 1999 classification with few additional
changes. Numerous subsequent studies demonstrated
that the WHO histologic classification is a significant
independent prognostic factor [5-10]. The cytologic diag-
nosis of thymomas is challenging. In part, this is because
the neoplasm is uncommon and aspirates are infre-
quently encountered [11]. The immunohistochemical
profile of thymomas is complex due to the variety of
growth patterns and background lymphoid infiltrate. We
studied a series of thymomas a) to correlate cytologic
morphology with the current WHO classification scheme,
and b) to further delineate type-specific immunopheno-
types with a focus on epithelial, neuroendocrine, and
lymphoid characteristics.
Methods
Data were evaluated retrospectively from patients who
underwent fine needle aspiration (FNA) cytology (n = 7)
and surgical treatment (n = 17) for thymoma at the Uni-
versity of Maryland Medical Center between 2000 and
2006. For cytologic examination utilizing CT guidance, 2–
3 FNAs using a 20 gauge Franseen needle were performed.
Air dried smears were prepared and stained with Diff
Quick for immediate cytological evaluation. After each
pass the needle was rinsed in RPMI medium. The rinsings
were cytocentrifuged and resulting smears were immedi-
ately fixed in 95% alcohol and stained by the Papanico-
laou method. Hematoxylin-eosin stained cell block
sections were available in all cases examined. Tissue sam-
ples from the surgical specimens were fixed in 10% for-
maldehyde and embedded in paraffin. Five-micron tissue
sections were stained with hematoxylin-eosin. The tumors
were classified according to the World Health Organiza-
tion criteria [1]. The scheme developed by Masaoka [12]
as modified by Koga et al. [13] was used for staging.
Immunohistochemistry
Immunohistochemical staining was performed using an
automated slide preparation system (Benchmark XT, Ven-
tana, Tuscon, AZ), a Ventana Biotin-Streptavidin (B-SA)
Enhanced DAB Detection Kit (Ventana, Tucson, AZ), and
commercially available prediluted monoclonal antibod-
ies: CD3, CD5, CD20, CD1a, CD99, calretinin, vimentin,
CK7, CK20, Epithelial Membrane Antigen (EMA), AE1/
AE3, CD57, Ki67, and bcl-2 (all Ventana, Tucson, AZ).
Results
Demographic and clinical data
There were eleven male and six female patients with an
age range of 41 to 84 years (mean, 61 years) and a male to
female ratio of 1.8:1. Four thymomas (4/17, 23.5%) were
associated with neuromuscular disease: myasthenia gravis
(n = 3) and limbic encephalitis (n = 1). All thymomas
associated with myasthenia gravis were type B3, whereas
limbic encephalitis occurred in a patient with type B2 thy-
moma.
Cytologic findings
Fine needle aspirates (FNAs) were moderately cellular.
Tissue fragments of variable size were frequently
observed. The aspirates consisted of a dual population of
oval or elongate epithelial cells and mature-appearing
lymphocytes. The neoplastic epithelial cells contained
round, oval or spindle pale nuclei with dispersed chroma-
tin and inconspicuous nucleoli (Figs. 1 and 2). The cyto-
plasm was scant, and the cell borders were ill-defined. The
nuclear/cytoplasmic ratio was moderate to high. Nuclear
pleomorphism was minimal; mitoses were not seen. In
two cases, the epithelial cells were obscured by a predom-
inant lymphocytic infiltration. Immunocytochemical
staining of cell block sections with pan-cytokeratin (AE1/
AE3) revealed the epithelial nature of the neoplastic cells.
Correlation of cytological diagnosis by FNA cytology with
the final histological diagnosis is shown in table 1. In two
cases, the aspirates were non-diagnostic. The positive pre-
dictive value for thymoma by FNA cytology was 100%
while the sensitivity was 71%.
Histologic and immunohistochemical findings
The pathological diagnoses, tumor stages, and immuno-
histochemical findings are presented in tables 2, 3, 4.
In type A thymoma, neoplastic epithelial cells stained
strongly for EMA, CK7, vimentin, and CD20. Immunos-
taining for CD57 and calretinin was noted in scattered
neoplastic epithelial cells. CK20, CD3, CD5, bcl-2, CD99,
and CD1a were all negative in neoplastic epithelium. The
few lymphocytes were CD3+ and CD5+, and CD20-,
CD1a- and CD99-. The Ki67 proliferation index was low
in neoplastic epithelial cells (<10%).
The type A component in AB thymomas showed an
immunophenotype virtually indistinguishable from the
one of type A neoplasms, including the strong expression
of vimentin (Figs. 3, 4, 5, 6). In the type B component, the
neoplastic epithelial cells were CK7-and variably EMA+,
vimentin +, and CD20+. Focal weak CD57 positivity was
also observed. The majority of non-neoplastic lym-
phocytes showed an immunophenotype characteristic of
immature T cells (CD3+, CD5+, CD1a+, CD99+; Ki67
proliferation index > 80%). Single CD57+ cytotoxic T
lymphocytes were rarely seen. The lymphocytes in foci of
medullary differentiation showed a mature T cell pheno-
type (CD3+, CD5+, CD1a-, CD99-; Ki67 proliferation
index <10%) and contained a large number of CD20+ B
lymphocytes.Diagnostic Pathology 2007, 2:13 http://www.diagnosticpathology.org/content/2/1/13
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In type B1 thymomas, neoplastic epithelial cells showed
expression of EMA and CK7 at the stromal interface, and
were consistently CD20, CK20, CD5, and vimentin nega-
tive. There were rare cells positive for CD57 and calretinin.
Admixed T lymphocytes were CD3+, CD5+, CD1a+,
CD99+, with high Ki67 proliferation index (>80%),
whereas lymphocytes in the medullary islands were
mature T cells (CD3+, CD5+, CD1a-, CD99-; Ki67 prolif-
eration index <10%) and CD20+ B cells. Few CD57+ cyto-
toxic T lymphocytes were also noted.
Type B2 and B3 thymomas showed a similar immunophe-
notype with a variable CK7 expression, and immature
intratumoral non-neoplastic T lymphocytes (CD3+,
CD5+, CD1a+, CD99+; Ki67 proliferation index >80%).
In type B2 thymomas, EMA was expressed in single neo-
plastic cells, whereas type B3 thymomas demonstrated an
expression of EMA at the tumor/stroma interface and
adjacent to cystic spaces. Small stromal lymphoid aggre-
gates containing mature T lymphocytes (CD3+, CD5+,
CD1a-, CD99-, Ki67 proliferation index <10%) and
CD20+ B lymphocytes were observed in all B2 and B3 thy-
momas. Scattered CD57+ cytotoxic T lymphocytes were
also noted. Vimentin was not expressed by neoplastic epi-
thelial cells. An unexpected observation was the diffuse
strong expression of CD57 in the majority of neoplastic
epithelial cells, large numbers of CD20+ intratumoral
lymphocytes and single CD20+ elongate fibroblast-like
cells in all thymomas associated with neuromuscular dis-
orders (Figs. 7, 8, 9). In contrast, sporadic thymomas con-
tained only few scattered CD57+ neoplastic epithelial
cells and CD20+ B cells (Figs. 10, 11, 12). Two of seven-
teen (11.7%) thymomas (all sporadic type B3) contained
numerous CD5+, bcl-2+ neoplastic epithelial cells (Figs.
13 and 14).
The sporadic micronodular thymoma (MNT) showed a
unique immunophenotype with neoplastic epithelial
cells strongly positive for EMA, CD57 (unlike other spo-
radic neoplasms), and focally for CK7 (Figs. 15, 16, 17,
18). CK20, CD20, vimentin, and CD5 were all negative.
The stroma contained large lymphocytic aggregates con-
taining a predominant cell population of CD20 B lym-
phocytes and mature T cells (CD3+, CD5+, CD1a-, CD99-
Table 1: Correlation of Cytological Diagnosis with Final Histological Diagnosis
Case Cytological Diagnosis Histological Diagnosis
1 Non-diagnostic Type B3 thymoma
2 Thymoma Type AB thymoma
3 Non-diagnostic Type B3 thymoma
4 Thymoma Type AB thymoma
5 Thymoma Type B1 thymoma
6 Thymoma Type A thymoma
7 Thymoma Type B1 thymoma
(Papanicolaou stain, × 200): Type AB thymoma Figure 1
(Papanicolaou stain, × 200): Type AB thymoma. FNA smear 
shows elongate neoplastic epithelial cells with oval or spindle 
pale nuclei and inconspicuous nucleoli.
(Papanicolaou stain, × 600): Type AB thymoma Figure 2
(Papanicolaou stain, × 600): Type AB thymoma. FNA smear 
shows neoplastic epithelial cells with dispersed chromatin 
and small nucleoli, and background lymphocytes.Diagnostic Pathology 2007, 2:13 http://www.diagnosticpathology.org/content/2/1/13
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, Ki67 proliferation index <10%). Intratumoral non-neo-
plastic immature T lymphocytes were numerous and
expressed CD3, CD5, CD1a, and CD99, with high Ki67
proliferation index (>80%).
Discussion
Thymoma is one of the major differential diagnostic con-
siderations in an adult patient > 40 years of age presenting
with a mediastinal mass. Aspirates of thymomas are dis-
tinguishable from other lesions, and FNA and CT-guided
core needle biopsy are proven methods for investigating
mediastinal masses [14]. The cytologic diagnosis of thy-
moma can be extremely challenging. In part, this is
because a technically proficient interventional radiologist
is needed, epithelial cells may be difficult to recognize in
lymphoid rich aspirate smears, and there is inherent sam-
pling error in a tumor that frequently displays heterogene-
ous histopathology [11]. In the present study the positive
predictive value for thymoma by FNA cytology was 100%
and sensitivity – 71%. Previous observations showed a
diagnostic sensitivity of 86% for FNAs [15] and 100% for
ultrasonically guided core needle biopsy [3], respectively.
Thymoma should be differentiated from other anterior
mediastinal neoplasms with epithelial and/or lymphoid
differentiation, including Non-Hodgkin (NHL) and
Hodgkin lymphomas, thymic carcinomas, and germ cell
malignancies. NHL and Hodgkin lymphoma can be sepa-
rated from thymoma by their dispersed cell population,
distinctive cytologic features, and positive staining for
CD45, CD20, CD15, and CD30, respectively. Helpful
cytologic and immunocytochemical features in making
the diagnosis of thymic carcinoma are clear-cut cytologi-
cal atypia, absence of immature lymphocytes (CD1a+,
CD99+), and expression of CD5 and CD70 by neoplastic
epithelial cells [16]. Mediastinal seminomas are immuno-
reactive for PLAP and CD117, while CD30 is expressed in
85–100% of embryonal carcinomas [1]. Similar to thy-
momas, mediastinal neuroendocrine neoplasms express
CD57 and other neuroendocrine markers but are consist-
ently negative for non-neoplastic immature lymphocytes
(CD1a+, CD99+). Limitations of the cytological method
include an unproven ability to definitively separate thy-
moma into specific WHO subtypes using cytology alone,
and to determine capsular invasion [11]. Overall, the
present study confirms previous observations [15,16] that
FNA of anterior mediastinal thymic lesions generally
Table 2: Pathologic Diagnosis and Thymoma Pathologic Staging*
Thymoma type Stage I Stage IIa Stage IIb Stage III Stage IVa
A  ( n  =  2 ) 11---
A B  ( n  =  3 ) 12---
B 1  ( n  =  4 ) 121--
B 2  ( n  =  1 ) -1---
B 3  ( n  =  6 ) 22-11
M N T  ( n  =  1 ) 1----
* = references 12 and 15
MNT = micronodular thymoma
Table 3: Immunohistochemical Results, Tumor Cell Expression
Marker Thymoma Type
A A BB 1B 2B 3M N T
E M A ++F o c a l S++
C K 7 ++ ^ ++++
C K 2 0 ------
C D 5 7 SSS+ * + * +
C D 5 ----- / + -
B c l - 2 ----- / + -
C a l r e t i n i n SSSSSS
V i m e n t i n + + ----
C D 2 0 + + ----
MNT= micronodular thymoma
S = single cells
+^ = neoplastic epithelial cells in type B component were CK7 negative
-/+ = variably (2 sporadic type B3 thymomas stained strongly positive)
+* = strong expression in type B2 (n = 1) and type B3 (n = 3) thymomas associated with autoimmune disorder; scattered positive neoplastic cells in 
sporadic thymomasDiagnostic Pathology 2007, 2:13 http://www.diagnosticpathology.org/content/2/1/13
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yields adequate cellular tissue with distinct cytologic and
immunophenotypic features that enables thymoma diag-
nosis.
Thymomas can exhibit a spectrum of autoimmune phe-
nomena, comprising neuromuscular, hematopoietic, der-
matologic, rheumatic/vasculitic, hepatic and renal
diseases [1]. In our study 4/17 (23.5%) thymomas were
associated with myasthenia gravis (n = 3) or limbic
encephalitis (n = 1). All thymomas with myasthenia
gravis were type B3 thymoma, whereas limbic encephali-
tis occurred in a patient with type B2 thymoma. All four
neoplasms displayed a diffuse strong expression of the
neuroendocrine marker CD57. In contrast, thymomas not
associated with neuromuscular disorders contained only
few scattered CD57+ neoplastic epithelial cells. Only few
studies have addressed the prevalence of neuroendocrine
differentiation in human thymic neoplasms and demon-
strated reactivity for synaptophysin, neuron-specific eno-
lase, and/or chromogranin in 58% thymic carcinomas
and atypical thymomas [17-20]. In addition, myasthenia
gravis was present in 2/6 thymus neoplasms with neu-
roendocrine differentiation [17]. Intriguingly, our cases
were dissimilar to those described in earlier reports in
terms of the CD57 positivity in type A and type AB thymo-
mas [21]. In their excellent study, Pan et al [21] reported
CD57 positivity in 76% short-spindled and 80% long-
spindled variants. Unfortunately, the CD57 staining was
not correlated with the presence or absence of autoim-
mune disease in thymoma patients. In this study, CD57
expression was seen only in scattered neoplastic epithelial
cells in type A thymomas. Focal weak CD57 positivity in
type AB thymomas was also noted. None of the type A and
type AB neoplasms were associated with a neuromuscular
Table 4: Immunohistochemical Results, Background Lymphocytes
Marker Thymoma Type
A A BB 1B 2B 3M N T
C D 5 7 SSSSSS
C D 3 S+++++
C D 5 S+++++
C D 2 0 - ++- / + - / + + *
C D 1 a - +++++
C D 9 9 - +++++
Ki67/MIB1 <10% >80% >80% >80% >80% >80%
MNT = multinodular thymoma
-/+ = variably (large numbers of intratumoral CD20+ lymphocytes in type B2 (n = 1) and type B3 (n = 3) thymomas associated with autoimmune 
disorder)
* = numerous large stromal CD20+ lymphoid aggregates
S = single cells
(hematoxylin-eosin, × 200): Type AB thymoma Figure 3
(hematoxylin-eosin, × 200): Type AB thymoma. Note type A 
and type B components. (hematoxylin-eosin, × 200)
(B-SA, anti-EMA, × 200): Type AB thymoma Figure 4
(B-SA, anti-EMA, × 200): Type AB thymoma. Neoplastic epi-
thelial cells in type A component express EMA.Diagnostic Pathology 2007, 2:13 http://www.diagnosticpathology.org/content/2/1/13
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disorder. This discrepancy cannot be explained at the
present time. Whether and in what percentage of cases
immunohistochemical reactivity for CD57 may be corre-
lated with clinical behavior and outcome remains a con-
troversial issue. The results of this study suggest that a
diffuse strong CD57 expression by neoplastic epithelial
cells has a high correlation with the concomitant presence
of a neuromuscular disease, notably myasthenia gravis.
The biologic significance of CD20 positivity in back-
ground lymphocytes remains unknown. As the data in
this study show, large numbers of intratumoral CD20+ B
lymphocytes were found in all 4 cases of thymoma associ-
ated with neuromuscular disorders, whereas sporadic thy-
momas contained only few scattered intratumoral CD20+
B cells. Numerous CD20+ B lymphocytes were also
observed in the medullary islands in type AB and type B1,
and in stromal lymphoid aggregates in type B2 and B3
thymomas.
In this context, Fend et al. [22] reported that large num-
bers of B cells with germinal centre formation were found
almost exclusively in myasthenia gravis-associated
tumors, mainly in cortical thymomas. As far as the occur-
rence of B-cell differentiation in medullary islands is con-
(B-SA, anti-vimentin, × 200): Type AB thymoma Figure 5
(B-SA, anti-vimentin, × 200): Type AB thymoma. Neoplastic 
epithelial cells in type A component express vimentin.
(B-SA, anti-CD20, × 200): Type AB thymoma Figure 6
(B-SA, anti-CD20, × 200): Type AB thymoma. Neoplastic 
epithelial cells in type A and B components express CD20.
(B-SA, anti-CD20, × 200): Type B3 thymoma associated with  myasthenia gravis Figure 7
(B-SA, anti-CD20, × 200): Type B3 thymoma associated with 
myasthenia gravis.
(B-SA, anti-CD57, × 200):Type B3 thymoma associated with  myasthenia gravis Figure 8
(B-SA, anti-CD57, × 200):Type B3 thymoma associated with 
myasthenia gravis. Strong expression of CD57 in the majority 
of neoplastic cells.Diagnostic Pathology 2007, 2:13 http://www.diagnosticpathology.org/content/2/1/13
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cerned, it has been suggested that a medullary
microenvironment with epidermoid cells corresponding
to Hassall's corpuscles seems to be necessary for specific
intrathymic B cell homing [22].
Surprisingly, we observed in type A and type AB thymo-
mas a large number of CD20+, EMA+, vimentin+ fibrob-
last-like elongate neoplastic epithelial cells. In type AB
neoplasms, the majority of positive cells were located in
the type A component and, to a lesser degree, in the type
B component, in the neoplastic epithelial meshwork. No
CD20+, vimentin+ neoplastic epithelial cells were seen in
type B thymomas. These data are in agreement with the
observed variable numbers of CD20+ spindle epithelial
cells in mixed thymomas [23] and suggest that neoplastic
epithelial cells in type A and type AB thymomas are dis-
tinctive and different from either B1, B2, B3 thymoma.
MNT is a rare neoplasm, characterized by a micronodular
growth pattern associated with florid lymphoid follicular
hyperplasia of the stroma [24]. In agreement with previ-
ous reports [24-26], in this study, the stromal lymphoid
cell population in the MNT contained numerous CD20+
(B-SA, anti-CD20, × 200): Type B3 thymoma associated with  myasthenia gravis Figure 9
(B-SA, anti-CD20, × 200): Type B3 thymoma associated with 
myasthenia gravis. Intratumoral lymphocytes and single 
fibroblast-like cells express CD20.
(hematoxylin-eosin, × 400): Type B3 thymoma not associated  with autoimmune disease Figure 10
(hematoxylin-eosin, × 400): Type B3 thymoma not associated 
with autoimmune disease.
(B-SA, anti-CD57, × 400): Type B3 thymoma not associated  with autoimmune disease Figure 11
(B-SA, anti-CD57, × 400): Type B3 thymoma not associated 
with autoimmune disease. Single neoplastic epithelial cells 
express CD57.
(B-SA, anti-CD20, × 400): Type B3 thymoma not associated  with autoimmune disease Figure 12
(B-SA, anti-CD20, × 400): Type B3 thymoma not associated 
with autoimmune disease. No CD20+ intratumoral lym-
phocytes are seen.Diagnostic Pathology 2007, 2:13 http://www.diagnosticpathology.org/content/2/1/13
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B cells and mature T cells, whereas intratumoral lym-
phocytes showed an immature T cell phenotype (CD3+,
CD1a+, CD99+, Ki67 proliferation index >80%). The bio-
logic significance of CD57 expression by neoplastic epi-
thelial cells in MNT is unknown. Unlike the type B2 and
B3 thymomas associated with neuromuscular disorders,
the MNT in this study did not contain CD20+ intratu-
moral lymphocytes. The patient had no clinical signs or
history of myasthenia gravis. Earlier studies have shown
that MNT is not associated with autoimmune disease [24].
Recent findings suggest that expression of chemoattract-
ants, such as CCL18, CCR6, and CCL20, on neoplastic
epithelium in MNT can promote the recruitment of
MALT, the emergence of monoclonal B cells, and, eventu-
ally, the subsequent development of mediastinal lym-
phoma [25].
Two of seventeen (11.7%) thymomas (all sporadic B3
type) contained numerous CD5+ and bcl-2+ neoplastic
epithelial cells. Previous studies showed that epithelial
cells in B3 thymomas are negative for CD5 [1]. The data
suggest that CD5 is not a reliable diagnostic marker for
primary thymic carcinomas since CD5 may be expressed
also in thymomas. The biologic significance of bcl-2
expression in neoplastic epithelium is unknown. Previous
(B-SA, anti-CD57, × 400): Type B3 thymoma Figure 13
(B-SA, anti-CD57, × 400): Type B3 thymoma. Note strong 
expression of CD5 in neoplastic epithelial cells and back-
ground lymphocytes.
(B-SA, anti-bcl-2, × 400): Type B3 thymoma Figure 14
(B-SA, anti-bcl-2, × 400): Type B3 thymoma. Note strong 
expression of bcl-2 in neoplastic epithelial cells and back-
ground lymphocytes.
(hematoxylin-eosin, × 100): Micronodular thymoma Figure 15
(hematoxylin-eosin, × 100): Micronodular thymoma.
(B-SA, anti-CD20, × 200): Micronodular thymoma Figure 16
(B-SA, anti-CD20, × 200): Micronodular thymoma. Note 
large lymphoid aggregates positive for CD20.Diagnostic Pathology 2007, 2:13 http://www.diagnosticpathology.org/content/2/1/13
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reports suggested that bcl-2 acts as an inhibitor of apopto-
sis in thymomas and correlates with aggressiveness in
thymic epithelial neoplasms [4,27,28].
Conclusion
In conclusion, the present report expands the spectrum of
our knowledge showing that thymomas associated with
autoimmune disorders contain a large population of
CD20+ intratumoral B lymphocytes. Strong CD57 posi-
tivity in neoplastic epithelial cells in thymomas may sug-
gest a concomitant neuromuscular disorder, notably
myasthenia gravis. Immunocytochemical analysis is use-
ful in assisting in the identification of these neoplasms
and in excluding other malignancies in CT-FNA. Limita-
tions of the cytological method include an inability to
definitively separate thymoma into specific WHO sub-
types using cytology alone, and to determine capsular
invasion. CD5 expression is of limited value in the differ-
ential diagnosis of primary thymic epithelial neoplasms
since both thymic carcinomas and thymomas may express
CD5.
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